Results 101 to 110 of about 5,507 (191)

Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2. [PDF]

Open Life Sci, 2023
Ruan Z, Tang J, Zeng M, Fan P.
europepmc   +1 more source

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100 , a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double‐blind study in healthy adults [PDF]

Susan Bodie, Aidan K. Curran, Aaron C. Gonzalez‐Nelson, Jason M. Perry, Debora C. Manning, Margaret Wasilewski   +5 more
openalex   +1 more source

Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog [PDF]

, 2008
Stephen B. Shrewsbury, Michael Stonerook, Jerry Okikawa   +2 more
openalex   +1 more source

An in silico investigation of allosteric inhibition potential of Dihydroergotamine against Sars-CoV-2 Main Protease (MPro)

, 2023
Mehmet Murat Yaşar, Ekrem Yaşar, Nuri Yorulmaz, Mehmet Emin Tenekeci, İsmail Hakkı SARPÜN, Erol Eroğlu   +5 more
openalex   +2 more sources

Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. [PDF]

J Headache Pain, 2023
Li G, Duan S, Zhu T, Ren Z, Xia H, Wang Z, Liu L, Liu Z.   +7 more
europepmc   +1 more source

Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors

, 2013
Shashidhar Kori, J Zhang, Donald Kellerman, Tom Armer, Peter J. Goadsby   +4 more
openalex   +1 more source

A CLINICAL COMPARISON OF SUMATRIPTAN NASAL SPRAY AND DIHYDROERGOTAMINE NASAL SPRAY IN THE ACUTE TREATMENT OF MIGRAINE [PDF]

, 2000
F. Boureau, Ludwig Kappos, Jean Schoenen, Paula Esperança, Elizabeth Ashford   +4 more
openalex   +1 more source

Unraveling Intractable Headache in Acute Myeloid Leukemia With Coexisting Migraines and Chiari Malformation. [PDF]

Cureus
Singla L, Austin HW.
europepmc   +1 more source

Aprepitant for the management of nausea with inpatient IV dihydroergotamine [PDF]

, 2016
Denise E. Chou, Amy R. Tso, Peter J. Goadsby   +2 more
openalex   +1 more source

STOP 101: A Phase 1, Randomized, Open‐Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD ^® ) Device, in Healthy Adult Subjects [PDF]

, 2019
Stephen B. Shrewsbury, Maria Jeleva, Kelsey Satterly, Jason D. Lickliter, John Hoekman   +4 more
openalex   +1 more source